574 related articles for article (PubMed ID: 31707465)
1. Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial.
Takada J; Dinavahi R; Miyauchi A; Hamaya E; Hirama T; Libanati C; Nakamura Y; Milmont CE; Grauer A
J Bone Miner Metab; 2020 May; 38(3):310-315. PubMed ID: 31707465
[TBL] [Abstract][Full Text] [Related]
2. Romosozumab in postmenopausal women with low bone mineral density.
McClung MR; Grauer A; Boonen S; Bolognese MA; Brown JP; Diez-Perez A; Langdahl BL; Reginster JY; Zanchetta JR; Wasserman SM; Katz L; Maddox J; Yang YC; Libanati C; Bone HG
N Engl J Med; 2014 Jan; 370(5):412-20. PubMed ID: 24382002
[TBL] [Abstract][Full Text] [Related]
3. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
Ishibashi H; Crittenden DB; Miyauchi A; Libanati C; Maddox J; Fan M; Chen L; Grauer A
Bone; 2017 Oct; 103():209-215. PubMed ID: 28687496
[TBL] [Abstract][Full Text] [Related]
4. Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study.
McClung MR; Brown JP; Diez-Perez A; Resch H; Caminis J; Meisner P; Bolognese MA; Goemaere S; Bone HG; Zanchetta JR; Maddox J; Bray S; Grauer A
J Bone Miner Res; 2018 Aug; 33(8):1397-1406. PubMed ID: 29694685
[TBL] [Abstract][Full Text] [Related]
5. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
[TBL] [Abstract][Full Text] [Related]
6. Twice-weekly teriparatide improves lumbar spine BMD independent of pre-treatment BMD and bone turnover marker levels.
Takada J; Yoshimura T; Uzawa T
J Bone Miner Metab; 2021 May; 39(3):484-493. PubMed ID: 33389132
[TBL] [Abstract][Full Text] [Related]
7. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
8. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.
Langdahl BL; Libanati C; Crittenden DB; Bolognese MA; Brown JP; Daizadeh NS; Dokoupilova E; Engelke K; Finkelstein JS; Genant HK; Goemaere S; Hyldstrup L; Jodar-Gimeno E; Keaveny TM; Kendler D; Lakatos P; Maddox J; Malouf J; Massari FE; Molina JF; Ulla MR; Grauer A
Lancet; 2017 Sep; 390(10102):1585-1594. PubMed ID: 28755782
[TBL] [Abstract][Full Text] [Related]
9. Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass.
Genant HK; Engelke K; Bolognese MA; Mautalen C; Brown JP; Recknor C; Goemaere S; Fuerst T; Yang YC; Grauer A; Libanati C
J Bone Miner Res; 2017 Jan; 32(1):181-187. PubMed ID: 27487526
[TBL] [Abstract][Full Text] [Related]
10. Association between P1NP and bone strength in postmenopausal women treated with teriparatide.
Chen FP; Fu TS; Lin YC; Sung CM; Huang MH; Lin YJ
Taiwan J Obstet Gynecol; 2022 Jan; 61(1):91-95. PubMed ID: 35181054
[TBL] [Abstract][Full Text] [Related]
11. Relationship between bone turnover and density with teriparatide, denosumab or both in women in the DATA study.
Tsai JN; Burnett-Bowie SM; Lee H; Leder BZ
Bone; 2017 Feb; 95():20-25. PubMed ID: 27840301
[TBL] [Abstract][Full Text] [Related]
12. Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass.
Keaveny TM; Crittenden DB; Bolognese MA; Genant HK; Engelke K; Oliveri B; Brown JP; Langdahl BL; Yan C; Grauer A; Libanati C
J Bone Miner Res; 2017 Sep; 32(9):1956-1962. PubMed ID: 28543940
[TBL] [Abstract][Full Text] [Related]
13. Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis.
Kashii M; Kamatani T; Nagayama Y; Miyama A; Tsuboi H; Ebina K
Osteoporos Int; 2023 Mar; 34(3):563-572. PubMed ID: 36585509
[TBL] [Abstract][Full Text] [Related]
14. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
Kendler DL; Roux C; Benhamou CL; Brown JP; Lillestol M; Siddhanti S; Man HS; San Martin J; Bone HG
J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
[TBL] [Abstract][Full Text] [Related]
16. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.
Fitzpatrick LA; Dabrowski CE; Cicconetti G; Gordon DN; Papapoulos S; Bone HG; Bilezikian JP
J Clin Endocrinol Metab; 2011 Aug; 96(8):2441-9. PubMed ID: 21593114
[TBL] [Abstract][Full Text] [Related]
17. Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide.
Blumsohn A; Marin F; Nickelsen T; Brixen K; Sigurdsson G; González de la Vera J; Boonen S; Liu-Léage S; Barker C; Eastell R;
Osteoporos Int; 2011 Jun; 22(6):1935-46. PubMed ID: 20938767
[TBL] [Abstract][Full Text] [Related]
18. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
19. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis.
Devogelaer JP; Adler RA; Recknor C; See K; Warner MR; Wong M; Krohn K
J Rheumatol; 2010 Jan; 37(1):141-8. PubMed ID: 19918047
[TBL] [Abstract][Full Text] [Related]
20. Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE.
Eastell R; Mitlak BH; Wang Y; Hu M; Fitzpatrick LA; Black DM
Osteoporos Int; 2019 Mar; 30(3):667-673. PubMed ID: 30635696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]